At-Home Transvaginal Pelvic Ultrasonography and Image Quality in Premenopausal Women: A Nonrandomized Clinical - Takeaways - MDSpire

At-Home Transvaginal Pelvic Ultrasonography and Image Quality in Premenopausal Women: A Nonrandomized Clinical

  • By

  • Alessandra J. Ainsworth

  • Caitlin Sacha

  • Stylianos Vagios

  • Ben Doke

  • Wendy Vitek

  • Dmitry Fridman

  • Tina Islam

  • Jillian Pecoriello

  • Jerome Chelliah

  • Annie Martini

  • Lauren Verrilli

  • Michelle Brown

  • Aaron Styer

  • July 6, 2026

  • 0 min

Share

  • 1

    Pelvic ultrasonography is a key diagnostic tool for gynecologic issues, but many women find the procedure uncomfortable and invasive.

  • 2

    Barriers to in-clinic transvaginal ultrasonography include time constraints, geographic distance, and the need for multiple procedures.

  • 3

    The SELF-GYN1 Trial evaluated the feasibility and participant experience of at-home transvaginal ultrasonography in premenopausal women.

  • 4

    Eligible participants were English-speaking premenopausal women aged 22 to 50, excluding those with certain gynecologic conditions.

  • 5

    Sonographers trained for 5 to 6 months guided participants remotely to capture required images for standard gynecologic imaging.

Original Source(s)

At-Home Transvaginal Pelvic Ultrasonography and Image Quality in Premenopausal Women: A Nonrandomized Clinical

  • by Alessandra J. Ainsworth, Caitlin Sacha, Stylianos Vagios, Ben Doke, Wendy Vitek, Dmitry Fridman, Tina Islam, Jillian Pecoriello, Jerome Chelliah, Annie Martini, Lauren Verrilli, Michelle Brown, Aaron Styer

  • July 6, 2026

Related Content

Why Is Vaginal Estrogen Still Underused?

A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.

Beyond the physician shortage: infrastructure as a rate-limiting step in breast cancer care

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability